This guideline addresses major issues related to cholesterol management and primary ASCVD prevention, which are also addressed in the recently published 2018 Cholesterol Clinical Practice …

Determines 10-year risk of hard ASCVD, i.e. myocardial infarction, stroke, or death due to coronary heart disease or stroke, and provides statin recommendations.

Recommend statins as first-line pharmacotherapy. Consider the combination of statin and nonstatin therapy in selected patients. Discuss potential risk reduction from lipid-lowering therapy. Discuss the …

Feb 5, 2025 · Use this patient-friendly summary of the guideline to help with shared decision-making with your patients to better understand the treatment options for reducing lipids and their risk of heart …

Several calculators exist including a Canadian one (Project Big Life). These calculators may be helpful to guide decision making in conjunction with clinical expertise.

Jun 2, 2025 · Historically, treatment focused on statins, with low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL as the threshold for treatment intensification, and nonstatins were reserved mainly for …

In patients who have a cardiovascular risk factor and an estimated 10-year CVD risk of 10% or greater, initiate a moderate-intensity statin after discussing the rationale and provided the patient...

Aug 23, 2022 · The USPSTF recommends that clinicians prescribe a statin for the primary prevention of CVD for adults aged 40 to 75 years who have 1 or more CVD risk factors (i.e. dyslipidemia, diabetes, …

Oct 1, 2025 · Statin therapy should involve shared decision making, considering polypharmacy, frailty, comorbidities, and side effects (Algorithm Fig. 8). Competing risks and life expectancy are crucial for …

Nov 14, 2024 · Today we'll be talking about statin initiation for primary prevention among statin-naive adults and reasons for non-adherence. Our latest guidelines for cholesterol management can be a bit …